Use of the drug verapamil to treat type 1 diabetes continues to show benefits lasting at least two years, according to a recent report in Nature Communications. Patients taking the oral blood pressure medication not only required less daily insulin two years after first diagnosis of the disease, but also showed evidence of surprising immunomodulatory benefits....
With the publication of “Eradicating Racism in Endocrinology: An Endocrine Society Policy Perspective” in the January issue of The Journal of Clinical Endocrinology & Metabolism, the Endocrine Society formally calls for policies to address racial and ethnic inequities in the endocrine workforce and in access to care. James Baldwin began his 1956 essay “Faulkner and...
Women with long or irregular periods are known to have a higher risk of type 2 diabetes and heart disease, but researchers found these women may also be at risk for nonalcoholic fatty liver disease (NAFLD), according to a new study published in The Journal of Clinical Endocrinology and Metabolism. About 24% of U.S. adults have...
A review recently published in Endocrinology offers some new insights on how maternal obesity-associated gestational diabetes (GDM) affects the reproductive health of offspring, discussing possible mechanisms, the latest perceptions, and highlighting areas that need further investigation. The review, by Niharika Sinha, PhD; Gretchen Lydia Walker; and Aritro Sen, PhD, all of Michigan State University in...
Glytec and Roche Diagnostics USA last month announced a digital health collaboration that combines Roche’s expertise in medical devices and IT solutions with Glytec’s FDA-cleared insulin dosing decision support software, Glucommander™, to address the pervasive challenges with inpatient blood sugar management at the hospital bedside. Glucommander will be the first software application available to run...
A newly discovered hormone named fabkin helps regulate metabolism and may play an important role in the development of both type 1 and type 2 diabetes, according to research led by the Sabri Ülker Center for Metabolic Research at Harvard T.H. Chan School of Public Health. The findings were published in Nature. The study showed blood...
The U.S. Food and Drug Administration (FDA) last month approved a rechargeable neurostimulator and a recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN). Medtronic is marketing the products as Intellis™ and Vanta™, respectively. DPN is a debilitating and progressive neurological disorder that affects approximately 30% of people with diabetes,...
A paper recently published in Endocrine Reviews looks to provide readers with an improved understanding in approaches to using hormone therapy to treat menopausal women. The review, by Valerie Flores, MD, and Lubna Pal, MD, of Yale School of Medicine and JoAnn Manson, MD, of Harvard Medical School, points out that hormone therapy remains the...
With the publication of “Eradicating Racism in Endocrinology: An Endocrine Society Policy Perspective” in the January issue of The Journal of Clinical Endocrinology & Metabolism, the Endocrine Society formally calls for policies to address racial and ethnic inequities in the endocrine workforce and in access to care. James Baldwin began his 1956 essay “Faulkner and...